Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1197-1204

  Ozaka, Masato ^a   Matsumura, Yuji ^b   Ishii, Hiroshi ^a   Omuro, Yasushi ^c   Itoi, Takao ^d   Mouri, Hisatsugu ^e   Hanada, Keiji ^f   Kimura, Yasutoshi ^g   Maetani, Iruru ^h   Okabe, Yoshinobu ⁱ   Tani, Masaji ^j   Ikeda, Takaaki ^k   Hijioka, Susumu ^l   Watanabe, Ryouhei ^m   Ohoka, Shinya ⁿ   Hirose, Yuki ^o   Suyama, Masafumi ^b   Egawa, Naoto ^c   Sofuni, Atsushi ^d   Ikari, Takaaki ^p   Nakajima, Toshifusa ^q   more..

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^d TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

^f JA Onomichi General Hospital   (Japan)

^g SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h TOHO UNIVERSITY OHASHI MEDICAL CENTER   (Japan)

ⁱ KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^k YOKOSUKA KYOSAI HOSPITAL   (Japan)

^l JAPANESE RED CROSS KUMAMOTO HOSPITAL   (Japan)

^m Matsuyama Shimin Hospital   (Japan)

ⁿ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^o FUKUI PREFECTURAL HOSPITAL   (Japan)

^p Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

^q Japan Clinical Cancer Research Organization   (Japan)

more..

Author keywords

Chemotherapy; Gemcitabine; Gemcitabine+S 1; S 1; Unresectable pancreatic cancer

Indexed keywords

GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CONTROL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; INOPERABLE CANCER; JAPAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NEUTROPHIL; OPEN STUDY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTE; THROMBOCYTOPENIA; ADENOCARCINOMA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; SURVIVAL RATE; TIME; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PANCREATIC NEOPLASMS; SURVIVAL RATE; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84862290986     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1822-1     Document Type: Article

References (17)

1. Ministry of Health, Labour and Welfare (2010) The dynamic statistics of the population in 2010. Available from http://www.mhlw.go.jp/toukei/saikin/hw/ jinkou/geppo/nengai08/toukei6.html. Accessed 26 July 2011
2. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413 (Pubitemid 27251144)
3. Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966 (Pubitemid 46972777)
4. Cunningham D et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513-5518
5. Saif MW et al (2009) S-1: a promising new oral Xuoropyrimidine derivative. Expert Opin Investig Drugs 18:335-348
6. Shirasaka T (2009) Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 39:2-15
7. Ueno H et al (2005) An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68:171-178 (Pubitemid 41158973)
8. Okusaka T et al (2008) A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61:615-621
9. Nakamura K et al (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94:1575-1579 (Pubitemid 43924916)
10. Lee GW et al (2009) Phase II trial of S-1 in combination with gemcitabine for chemo-naive patients with locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol 64: 707-713
11. Kim MK et al (2009) S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer. Jpn J Clin Oncol 39:49-53
12. Oh DY et al (2010) A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer. Cancer Chemother Pharmacol 65:527-536
13. Ueno H et al (2011) Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol
14. Ioka T et al (2011) Randomized phase III study of gemcitabine plus S-1 versus S-1 versus gemcitabine in unresectable advanced pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol 29(suppl; abstr 4007)
15. Berlin JD et al (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270-3275 (Pubitemid 34831525)
16. Cunningham D et al (2009) Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 27:5513-5518
17. Isayama H et al (2011) The final analysis of a multicenter randomized controlled trial of gemcitabine (G) alone versus gemcitabine and S-1 combination therapy (GS) in patients with unresectable advanced pancreatic cancer (PC): GEMSAP study. J Clin Oncol 29(suppl; abstr 4040)